The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title Content PDF
5/07/2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia.
2/07/2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019
26/06/2019 Información sobre dividendos The Company informs about the dividends payment
12/06/2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting
8/05/2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting
8/05/2019 Information on P&L ROVI releases the press release related to the first quarter 2019 financial results
8/05/2019 Information on P&L ROVI releases the first quarter 2019 results presentation
7/05/2019 Liquidity contracts and specialists ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A.    
30/04/2019 Liquidity contracts and specialists ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U.    
11/04/2019 Strategic agreements with third parties The Company releases the press release related to the marketing agreement of Tetridar® in Spain  

Pages